Compound Danshen Dripping Pills

ApprovedSmall molecule

Compound Danshen Dripping Pills is one of 77 small molecule programs targeting Diabetic Retinopathy. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic RetinopathyActive, not recruiting

Heart DiseaseActive, not recruiting

Diabetic RetinopathyPhase 3

Active, not recruiting

Heart DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

166 competitors in Heart Disease

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Phase 3

1 2

Lopid

Pfizer

Phase 3

1 3

Biaxin

AbbVie

Phase 3

1 4

Aldactone

Pfizer

Phase 3

1 5

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

9 6

Depo-Provera

Eli Lilly

Phase 3

—7

Zoloft

VViatris Specialty LLC

Phase 3

2 8

Comparator: Statins

Merck & Co.

Phase 3

1 9

Levophed

GGeneral Hospital of Ningxia Medical University

Phase 3

—10

Zesly

MMezzion Pharma Co. Ltd

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Heart Disease

NCT07041359

Clinical

Trials by Indication[1]

Diabetic Retinopathy1 trial

Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy

Unknown status·TTasly Pharmaceuticals, Inc.·Phase 3·NCT02388984·480 enrolled

Heart Disease1 trial

Pre-trial of Clinical Trial of Traditional Chinese Medicine Treatment for Elderly Patients With Coronary Heart Disease Who Are Still Symptomatic After Optimal Medical Treatment

Recruiting·CChina National Center for Cardiovascular Diseases·Phase 4·NCT07041359·120 enrolled

Acute Mountain Sickness1 trial

Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness

Completed·TTasly Pharmaceuticals, Inc.·Phase 1/2·NCT03270787·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Compound Danshen Dripping Pills. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Compound Danshen Dripping Pills compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Compound Danshen Dripping Pills. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tasly Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TTasly Pharmaceuticals, Inc.

Compound Danshen Dripping Pills

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Diabetic Retinopathy1 trial

Heart Disease1 trial

Acute Mountain Sickness1 trial

References

Drug Info

Quick Facts

Related News